Somnomed Limited (SOMNF)
OTHER OTC:SOMNF
SOMNF Stock Chart & Stats
$0.41
-$0.01(-6.29%)
At close: 4:00 PM EST
$0.41
-$0.01(-6.29%)
Day’s Range― - ―
52-Week Range$0.31 - $0.56
Previous CloseN/A
Volume17.00K
Average Volume (3M)0.00
Market Cap
$95.98M
Enterprise Value$132.91M
Total Cash (Recent Filing)$18.03M
Total Debt (Recent Filing)$14.01M
Price to Earnings (P/E)52.9
Beta0.54
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,083,250
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.97
Price to Sales (P/S)1.24
P/FCF Ratio25.69
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue1.12
Enterprise Value/Gross Profit1.95
Enterprise Value/Ebitda31.83
Forecast
1Y Price Target
$0.70Price Target Upside70.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained top-line growth shows ongoing adoption of Somnomed's oral appliance therapy and successful clinician channel penetration. Durable revenue increases support investment in product development, distribution and clinician education, improving prospects for scale and long-term market share gains.
Improved Cash GenerationA marked jump in free cash flow and positive operating cash flow to net income indicate the company can fund operations and growth internally. Strong cash conversion reduces reliance on external financing, supports R&D and go-to-market spend, and cushions the business through execution cycles.
High Gross MarginsA roughly 60% gross margin suggests efficient manufacturing and pricing power for custom oral devices. High product-level margins give Somnomed room to absorb fixed SG&A and scale toward profitability as revenue grows, supporting sustainable operating leverage over time.
Bears Say
Persistent UnprofitabilityOngoing negative net and EBIT margins reflect that core operations are not yet profitable after overhead. Without structural margin improvement or substantial scale, continued losses could erode cash reserves or force dilution, making profitability a multi-quarter structural challenge.
Negative Return On EquityA negative ROE signals capital is not producing positive returns, undermining long-term shareholder value. This structural shortfall pressures management to improve operational efficiency or capital allocation, and may limit investor confidence until returns normalize.
Dependence On Clinician Adoption & ReimbursementRevenue growth depends heavily on clinician uptake, diagnosis/referral volumes and reimbursement policies. These structural external factors produce long sales cycles and exposure to payer/regulatory shifts, constraining predictable scaling and making execution dependent on sustained clinician and payer engagement.
Somnomed Limited News
SOMNF FAQ
What was Somnomed Limited’s price range in the past 12 months?
Somnomed Limited lowest stock price was $0.31 and its highest was $0.56 in the past 12 months.
What is Somnomed Limited’s market cap?
Somnomed Limited’s market cap is $95.98M.
When is Somnomed Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Somnomed Limited’s earnings last quarter?
Currently, no data Available
Is Somnomed Limited overvalued?
According to Wall Street analysts Somnomed Limited’s price is currently Undervalued.
Does Somnomed Limited pay dividends?
Somnomed Limited does not currently pay dividends.
What is Somnomed Limited’s EPS estimate?
Somnomed Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Somnomed Limited have?
Somnomed Limited has 219,083,250 shares outstanding.
What happened to Somnomed Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Somnomed Limited?
Currently, no hedge funds are holding shares in SOMNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Somnomed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
181.70%
12-Months-Change
Fundamentals
Return on Equity
-5.31%
Trailing 12-Months
Asset Growth
14.75%
Trailing 12-Months
Company Description
Somnomed Limited
SomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. It offers SomnoDent, an oral appliance for obstructive sleep apnea; SomnoBrux, a dental guard for the treatment of teeth grinding damage; SomMorning Repositioner, which help return mandible back to its pre-treatment centric position; and SomTabs for cleaning oral devices. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.
SOMNF Company Deck
SOMNF Earnings Call
Q2 2026
0:00 / 0:00
SOMNF Stock 12 Month Forecast
Average Price Target
$0.70
▲(70.73% Upside)
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Cyclopharm Limited
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Ownership Overview
Options Prices
Currently, No data available
---